ReviewBiology2020
Pathogenesis of Osteoarthritis: Risk Factors, Regulatory Pathways in Chondrocytes, and Experimental Models.
Review in Biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 205 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
205 citing papers in PubMed, 5 syntheses or guidelines pooled it, 350 citations in OpenAlex.
- Preclinical pharmacological effects of epimedium-derived interventions in osteoarthritis: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Predictive Value of Machine Learning in Knee Osteoarthritis Progression: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2025Pooled it
- Predictive Performance of Raman Spectroscopy in Osteoarthritis: A Systematic Review.Journal of medical systems · 2025Pooled it
- Efficacy and Mechanisms ofCurrent rheumatology reviews · 2024Pooled it
- Pooled it
- Trial
- Association between medial meniscal extrusion and knee structural progression in adults with symptomatic knee osteoarthritis - a prospective cohort study.Skeletal radiology · 2025Trial
- Randomized, double-blind, placebo-controlled study to evaluate the effect of treatment with an SPMs-enriched oil on chronic pain and inflammation, functionality, and quality of life in patients with symptomatic knee osteoarthritis: GAUDI study.Journal of translational medicine · 2023Trial
- Inhibition of Hexokinase 2 Undermines Cartilage Health and Accelerates Osteoarthritis.Cartilage · 2026Article
- Bioenergetic Materials for Tissue Regeneration: Modulating Metabolism to Promote Cellular Anabolism.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Knee Osteoarthritis and Metabolic Disorders: Practical Aspects from Primary Healthcare.Journal of clinical medicine · 2026Article
- Ribosome biogenesis in osteoarthritis: mechanisms and therapeutic potential.Journal of translational medicine · 2026Review
- Chondroprotective Effects of Enzyme-Treated Extract fromInternational journal of molecular sciences · 2026Article
- Advanced glycation end product accumulation and AGEs-RAGE axis biomarkers in plasma and synovial fluid are associated with osteoarthritis severity.Biomolecules & biomedicine · 2026Observational
- Integrated hydrogel system targeting AMPK/PPARγ signaling in osteoarthritis immunometabolic regulation.Journal of nanobiotechnology · 2026Article
- Osteoarthritis phenotypes: advancing precision medicine through clinical, structural, and molecular stratification.International orthopaedics · 2026Review
- Physical Therapy-Based Realignment Strategies for Knee Osteoarthritis: A Systematic Review.Cureus · 2026Review
- Deficiency of the mCellular and molecular life sciences : CMLS · 2026Article
- Cellular Products with Anti-Inflammatory Properties for the Treatment of Cartilage Lesions.International journal of molecular sciences · 2026Review
- Early Post‑Traumatic Osteoarthritis Features Greater Cartilage Extracellular Matrix Proteoglycan Loss Compared to the Pericellular Matrix.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2026Article
145 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
Abstract
As the most common chronic degenerative joint disease, osteoarthritis (OA) is the leading cause of pain and physical disability, affecting millions of people worldwide. Mainly characterized by articular cartilage degradation, osteophyte formation, subchondral bone remodeling, and synovial inflammation, OA is a heterogeneous disease that impacts all component tissues of the articular joint organ. Pathological changes, and thus symptoms, vary from person to person, underscoring the critical need of personalized therapies. However, there has only been limited progress towards the prevention and treatment of OA, and there are no approved effective disease-modifying osteoarthritis drugs (DMOADs). Conventional treatments, including non-steroidal anti-inflammatory drugs (NSAIDs) and physical therapy, are still the major remedies to manage the symptoms until the need for total joint replacement. In this review, we provide an update of the known OA risk factors and relevant mechanisms of action. In addition, given that the lack of biologically relevant models to recapitulate human OA pathogenesis represents one of the major roadblocks in developing DMOADs, we discuss current in vivo and in vitro experimental OA models, with special emphasis on recent development and application potential of human cell-derived microphysiological tissue chip platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.